SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-144993
Filing Date
2022-05-09
Accepted
2022-05-09 16:11:40
Documents
14
Period of Report
2022-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d331553d8k.htm   iXBRL 8-K 24612
2 EX-99.1 d331553dex991.htm EX-99.1 54089
6 GRAPHIC g331553g0509225721096.jpg GRAPHIC 3382
  Complete submission text file 0001193125-22-144993.txt   212765

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akba-20220509.xsd EX-101.SCH 2841
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20220509_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20220509_pre.xml EX-101.PRE 10802
8 EXTRACTED XBRL INSTANCE DOCUMENT d331553d8k_htm.xml XML 3230
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 22905050
SIC: 2834 Pharmaceutical Preparations